© 2023 Copyright, Verseau Therapeutics, Inc. All Rights Reserved.

Daniel Anderson, Ph.D.

Co-Founder, Verseau
Professor, Applied Biology, Koch Institute, MIT

Dr. Daniel Anderson is a Co-Founder of Verseau and has served as a board member since March 2017. He is a leading researcher in the field of nanotherapeutics and biomaterials. He is appointed in the Department of Chemical Engineering, the Institute for Medical Engineering and Science, the Koch Institute for Integrative Cancer Research, and the Harvard-MIT Division of Health Science and Technology at MIT. The research done in his laboratory is focused on developing new materials for medicine. He has pioneered the development of smart biomaterials, and his work has led to advances in a range of areas, including medical devices, cell therapy, drug delivery, gene therapy and material science. Dan received a B.A. in mathematics and biology from the University of California at Santa Cruz and a Ph.D. in molecular genetics from the University of California at Davis. Dan’s work has resulted in the publication of over 400 papers, patents and patent applications. These advances have led to products that have been commercialized or are in clinical development, as well as to the foundation of companies in the pharmaceutical, biotechnology, and consumer product spaces including CRISPR Tx (Nasdaq:CRSP), Living Proof, Sigilon and Olivo Labs.


Daniel Anderson, Ph.D.

Co-Founder, Verseau
Professor, Applied Biology, Koch Institute, MIT

Dr. Daniel Anderson is a Co-Founder of Verseau and has served as a board member since March 2017. He is a leading researcher in the field of nanotherapeutics and biomaterials. He is appointed in the Department of Chemical Engineering, the Institute for Medical Engineering and Science, the Koch Institute for Integrative Cancer Research, and the Harvard-MIT Division of Health Science and Technology at MIT. The research done in his laboratory is focused on developing new materials for medicine. He has pioneered the development of smart biomaterials, and his work has led to advances in a range of areas, including medical devices, cell therapy, drug delivery, gene therapy and material science. Dan received a B.A. in mathematics and biology from the University of California at Santa Cruz and a Ph.D. in molecular genetics from the University of California at Davis. Dan’s work has resulted in the publication of over 400 papers, patents and patent applications. These advances have led to products that have been commercialized or are in clinical development, as well as to the foundation of companies in the pharmaceutical, biotechnology, and consumer product spaces including CRISPR Tx (Nasdaq:CRSP), Living Proof, Sigilon and Olivo Labs.


Daniel Anderson, Ph.D.

Co-Founder, Verseau
Professor, Applied Biology, Koch Institute, MIT

Dr. Daniel Anderson is a Co-Founder of Verseau and has served as a board member since March 2017. He is a leading researcher in the field of nanotherapeutics and biomaterials. He is appointed in the Department of Chemical Engineering, the Institute for Medical Engineering and Science, the Koch Institute for Integrative Cancer Research, and the Harvard-MIT Division of Health Science and Technology at MIT. The research done in his laboratory is focused on developing new materials for medicine. He has pioneered the development of smart biomaterials, and his work has led to advances in a range of areas, including medical devices, cell therapy, drug delivery, gene therapy and material science. Dan received a B.A. in mathematics and biology from the University of California at Santa Cruz and a Ph.D. in molecular genetics from the University of California at Davis. Dan’s work has resulted in the publication of over 400 papers, patents and patent applications. These advances have led to products that have been commercialized or are in clinical development, as well as to the foundation of companies in the pharmaceutical, biotechnology, and consumer product spaces including CRISPR Tx (Nasdaq:CRSP), Living Proof, Sigilon and Olivo Labs.


Jong Chang

Founder & Chairman, InHarv Partners

Jong Chang has served as a board member of Verseau since March 2017. He is the Founder and Chairman of InHarv Partners Ltd., a hybrid of VC and private equity based in Seoul, Korea whose strategic stance is to raise capital in South Korea for investment in cutting edge tech startups overseas, linking those startups to the Korean industries. He was previously Lead Partner of Booz Allen Hamilton, a global general management consultancy in the U.S., and a Senior Vice President and founding member of KBRI (now Moody’s Korea Inc.), the first credit rating agency in Seoul. As a previous corporate finance manager of the Korea Merchant Bank Corporation, a joint venture with Lazard Brothers U.K., Jong specialized in international mega-project financing and cross border M&As. He served as Junior Economist of the Korea Development Bank and as a member of The National Economic Counsel to Mr. President of South Korea. Jong also held positions as an independent board member of LG Chemical Co. of the LG Group based in Seoul and as an independent board member of Saint-Gabain Korea, a leading flat glass maker. Presently, Jong is the Chairman of the Board of ToolGen, Inc. a world leading DNA editing company based in Seoul Korea. Jong graduated cum laude with a B.A. from So-Gang University in South Korea and holds his MBA from the Wharton School of Business at the University of Pennsylvania.


Jong Chang

Founder & Chairman, InHarv Partners

Jong Chang has served as a board member of Verseau since March 2017. He is the Founder and Chairman of InHarv Partners Ltd., a hybrid of VC and private equity based in Seoul, Korea whose strategic stance is to raise capital in South Korea for investment in cutting edge tech startups overseas, linking those startups to the Korean industries. He was previously Lead Partner of Booz Allen Hamilton, a global general management consultancy in the U.S., and a Senior Vice President and founding member of KBRI (now Moody’s Korea Inc.), the first credit rating agency in Seoul. As a previous corporate finance manager of the Korea Merchant Bank Corporation, a joint venture with Lazard Brothers U.K., Jong specialized in international mega-project financing and cross border M&As. He served as Junior Economist of the Korea Development Bank and as a member of The National Economic Counsel to Mr. President of South Korea. Jong also held positions as an independent board member of LG Chemical Co. of the LG Group based in Seoul and as an independent board member of Saint-Gabain Korea, a leading flat glass maker. Presently, Jong is the Chairman of the Board of ToolGen, Inc. a world leading DNA editing company based in Seoul Korea. Jong graduated cum laude with a B.A. from So-Gang University in South Korea and holds his MBA from the Wharton School of Business at the University of Pennsylvania.


Jong Chang

Founder & Chairman, InHarv Partners

Jong Chang has served as a board member of Verseau since March 2017. He is the Founder and Chairman of InHarv Partners Ltd., a hybrid of VC and private equity based in Seoul, Korea whose strategic stance is to raise capital in South Korea for investment in cutting edge tech startups overseas, linking those startups to the Korean industries. He was previously Lead Partner of Booz Allen Hamilton, a global general management consultancy in the U.S., and a Senior Vice President and founding member of KBRI (now Moody’s Korea Inc.), the first credit rating agency in Seoul. As a previous corporate finance manager of the Korea Merchant Bank Corporation, a joint venture with Lazard Brothers U.K., Jong specialized in international mega-project financing and cross border M&As. He served as Junior Economist of the Korea Development Bank and as a member of The National Economic Counsel to Mr. President of South Korea. Jong also held positions as an independent board member of LG Chemical Co. of the LG Group based in Seoul and as an independent board member of Saint-Gabain Korea, a leading flat glass maker. Presently, Jong is the Chairman of the Board of ToolGen, Inc. a world leading DNA editing company based in Seoul Korea. Jong graduated cum laude with a B.A. from So-Gang University in South Korea and holds his MBA from the Wharton School of Business at the University of Pennsylvania.


Robert Langer, Ph.D.

Co-Founder, Verseau
David H. Koch Professor, Koch Institute, MIT

Dr. Robert Langer is a Co-Founder of Verseau and has served as a board member since March 2017. He is an Institute Professor at the Massachusetts Institute of Technology (MIT). He has written over 1,200 articles, which have been cited over 90,000 times; his h-index of 148 is the highest of any engineer in history. He has 815 issued and pending patents worldwide. His patents have been licensed or sublicensed to over 250 companies. He served as Chairman of the FDA’s Science Board (its highest advisory board) from 1999-2002. His over 220 awards include both the United States National Medal of Science and the United States National Medal of Technology and Innovation, as well as the Charles Stark Draper Prize (considered the engineering Nobel Prize), Albany Medical Center Prize, the Wolf Prize for Chemistry, the Millennium Technology Prize, the Priestley Medal (highest award of the American Chemical Society), the Gairdner Prize and the Lemelson-MIT prize, for being “one of history’s most prolific inventors in medicine.” He holds 20 honorary doctorates, including honorary degrees from Harvard University and Yale University. Dr. Langer is one of the few individuals ever to have been elected to the Institute of Medicine, the National Academy of Engineering, the National Academy of Sciences and the National Academy of Inventors.


Robert Langer, Ph.D.

Co-Founder, Verseau
David H. Koch Professor, Koch Institute, MIT

Dr. Robert Langer is a Co-Founder of Verseau and has served as a board member since March 2017. He is an Institute Professor at the Massachusetts Institute of Technology (MIT). He has written over 1,200 articles, which have been cited over 90,000 times; his h-index of 148 is the highest of any engineer in history. He has 815 issued and pending patents worldwide. His patents have been licensed or sublicensed to over 250 companies. He served as Chairman of the FDA’s Science Board (its highest advisory board) from 1999-2002. His over 220 awards include both the United States National Medal of Science and the United States National Medal of Technology and Innovation, as well as the Charles Stark Draper Prize (considered the engineering Nobel Prize), Albany Medical Center Prize, the Wolf Prize for Chemistry, the Millennium Technology Prize, the Priestley Medal (highest award of the American Chemical Society), the Gairdner Prize and the Lemelson-MIT prize, for being “one of history’s most prolific inventors in medicine.” He holds 20 honorary doctorates, including honorary degrees from Harvard University and Yale University. Dr. Langer is one of the few individuals ever to have been elected to the Institute of Medicine, the National Academy of Engineering, the National Academy of Sciences and the National Academy of Inventors.


Robert Langer, Ph.D.

Co-Founder, Verseau
David H. Koch Professor, Koch Institute, MIT

Dr. Robert Langer is a Co-Founder of Verseau and has served as a board member since March 2017. He is an Institute Professor at the Massachusetts Institute of Technology (MIT). He has written over 1,200 articles, which have been cited over 90,000 times; his h-index of 148 is the highest of any engineer in history. He has 815 issued and pending patents worldwide. His patents have been licensed or sublicensed to over 250 companies. He served as Chairman of the FDA’s Science Board (its highest advisory board) from 1999-2002. His over 220 awards include both the United States National Medal of Science and the United States National Medal of Technology and Innovation, as well as the Charles Stark Draper Prize (considered the engineering Nobel Prize), Albany Medical Center Prize, the Wolf Prize for Chemistry, the Millennium Technology Prize, the Priestley Medal (highest award of the American Chemical Society), the Gairdner Prize and the Lemelson-MIT prize, for being “one of history’s most prolific inventors in medicine.” He holds 20 honorary doctorates, including honorary degrees from Harvard University and Yale University. Dr. Langer is one of the few individuals ever to have been elected to the Institute of Medicine, the National Academy of Engineering, the National Academy of Sciences and the National Academy of Inventors.


Anna Turetsky, Ph.D.

Principal, Venture Investments, The Mark Foundation for Cancer Research

Dr. Anna Turetsky has served as a board member of Verseau since March 2021 and was previously a board observer. Anna Turetsky joined The Mark Foundation for Cancer Research (MFCR) as Principal, Venture Investments in November 2019 to launch and lead the foundation’s venture arm. She currently represents MFCR on the boards of Verseau, Accent Therapeutics, C2i Genomics, and Interius BioTherapeutics. Prior to this, Anna was a Vice President at Lightstone Ventures, a global, early-stage venture fund investing in the biopharmaceutical and medical device sectors. She played a major role in the firm’s investments in Tizona Therapeutics, Gemini Therapeutics (NASDAQ:GMTX), Disarm Therapeutics (acquired by Eli Lilly), Locanabio, and Cyteir Therapeutics, and served as board observer for these companies. Anna’s additional work experience includes internships and strategic consulting for corporate venture funds and biotech companies. Anna holds a Ph.D. in biophysics from Harvard University, where she was an NSF Graduate Research Fellow, and a B.A. in biochemistry from the University of Pennsylvania, where she was a Vagelos Science Scholar.


Anna Turetsky, Ph.D.

Principal, Venture Investments, The Mark Foundation for Cancer Research

Dr. Anna Turetsky has served as a board member of Verseau since March 2021 and was previously a board observer. Anna Turetsky joined The Mark Foundation for Cancer Research (MFCR) as Principal, Venture Investments in November 2019 to launch and lead the foundation’s venture arm. She currently represents MFCR on the boards of Verseau, Accent Therapeutics, C2i Genomics, and Interius BioTherapeutics. Prior to this, Anna was a Vice President at Lightstone Ventures, a global, early-stage venture fund investing in the biopharmaceutical and medical device sectors. She played a major role in the firm’s investments in Tizona Therapeutics, Gemini Therapeutics (NASDAQ:GMTX), Disarm Therapeutics (acquired by Eli Lilly), Locanabio, and Cyteir Therapeutics, and served as board observer for these companies. Anna’s additional work experience includes internships and strategic consulting for corporate venture funds and biotech companies. Anna holds a Ph.D. in biophysics from Harvard University, where she was an NSF Graduate Research Fellow, and a B.A. in biochemistry from the University of Pennsylvania, where she was a Vagelos Science Scholar.


Anna Turetsky, Ph.D.

Principal, Venture Investments, The Mark Foundation for Cancer Research

Dr. Anna Turetsky has served as a board member of Verseau since March 2021 and was previously a board observer. Anna Turetsky joined The Mark Foundation for Cancer Research (MFCR) as Principal, Venture Investments in November 2019 to launch and lead the foundation’s venture arm. She currently represents MFCR on the boards of Verseau, Accent Therapeutics, C2i Genomics, and Interius BioTherapeutics. Prior to this, Anna was a Vice President at Lightstone Ventures, a global, early-stage venture fund investing in the biopharmaceutical and medical device sectors. She played a major role in the firm’s investments in Tizona Therapeutics, Gemini Therapeutics (NASDAQ:GMTX), Disarm Therapeutics (acquired by Eli Lilly), Locanabio, and Cyteir Therapeutics, and served as board observer for these companies. Anna’s additional work experience includes internships and strategic consulting for corporate venture funds and biotech companies. Anna holds a Ph.D. in biophysics from Harvard University, where she was an NSF Graduate Research Fellow, and a B.A. in biochemistry from the University of Pennsylvania, where she was a Vagelos Science Scholar.


Hillel Bachrach

Founder and Managing Partner at 20/20 Healthcare Partners, LLC

Hillel is the Managing Partner of 20/20 HealthCare Partners, LLC, (20/20 HCP), a global investment entity he founded in 2005. 20/20 HCP has invested in many successful companies including Viztek (acquired by Konica Minolta in 2015), Corindus Vascular Robotics (purchased by Siemens HealthCare in 2019), XR Health, SQZ Biotechnology, Verseau Therapeutics and EnClear Therapies. In addition to Variantyx, Hillel currently serves on the Board of Directors for Zixi, Coagulo and NemDx. Hillel previously served as president of Odin Medical Technologies, Inc., and helped found UltraSPECT, Ltd. which was sold to Pharmalogic in 2019. Hillel received a BS in electrical engineering from Technion Israeli Institute of Technology and an MBA from the Kellogg Graduate School of Management.


Hillel Bachrach

Founder and Managing Partner at 20/20 Healthcare Partners, LLC

Hillel is the Managing Partner of 20/20 HealthCare Partners, LLC, (20/20 HCP), a global investment entity he founded in 2005. 20/20 HCP has invested in many successful companies including Viztek (acquired by Konica Minolta in 2015), Corindus Vascular Robotics (purchased by Siemens HealthCare in 2019), XR Health, SQZ Biotechnology, Verseau Therapeutics and EnClear Therapies. In addition to Variantyx, Hillel currently serves on the Board of Directors for Zixi, Coagulo and NemDx. Hillel previously served as president of Odin Medical Technologies, Inc., and helped found UltraSPECT, Ltd. which was sold to Pharmalogic in 2019. Hillel received a BS in electrical engineering from Technion Israeli Institute of Technology and an MBA from the Kellogg Graduate School of Management.


Hillel Bachrach

Founder and Managing Partner at 20/20 Healthcare Partners, LLC

Hillel is the Managing Partner of 20/20 HealthCare Partners, LLC, (20/20 HCP), a global investment entity he founded in 2005. 20/20 HCP has invested in many successful companies including Viztek (acquired by Konica Minolta in 2015), Corindus Vascular Robotics (purchased by Siemens HealthCare in 2019), XR Health, SQZ Biotechnology, Verseau Therapeutics and EnClear Therapies. In addition to Variantyx, Hillel currently serves on the Board of Directors for Zixi, Coagulo and NemDx. Hillel previously served as president of Odin Medical Technologies, Inc., and helped found UltraSPECT, Ltd. which was sold to Pharmalogic in 2019. Hillel received a BS in electrical engineering from Technion Israeli Institute of Technology and an MBA from the Kellogg Graduate School of Management.


Diane Xue

General Counsel, 3SBio Inc.

Diane Xue has served as a board member of Verseau since June 2022. Diane is the General Counsel of 3SBio Inc. Prior to joining 3SBio, Diane was a partner at a leading PRC law firm where she practiced law for six years. Prior to this, Diane worked as an associate at two leading U.S. law firms for about 10 years and a leading PRC law firm for about three years. Diane has extensive experiences in mergers and acquisitions, licencing transactions, private equity and venture capital investments. Diane holds a bachelor degree in law from Beijing University and a master degree in law from New York University School of Law.


Diane Xue

General Counsel, 3SBio Inc.

Diane Xue has served as a board member of Verseau since June 2022. Diane is the General Counsel of 3SBio Inc. Prior to joining 3SBio, Diane was a partner at a leading PRC law firm where she practiced law for six years. Prior to this, Diane worked as an associate at two leading U.S. law firms for about 10 years and a leading PRC law firm for about three years. Diane has extensive experiences in mergers and acquisitions, licencing transactions, private equity and venture capital investments. Diane holds a bachelor degree in law from Beijing University and a master degree in law from New York University School of Law.


Diane Xue

General Counsel, 3SBio Inc.

Diane Xue has served as a board member of Verseau since June 2022. Diane is the General Counsel of 3SBio Inc. Prior to joining 3SBio, Diane was a partner at a leading PRC law firm where she practiced law for six years. Prior to this, Diane worked as an associate at two leading U.S. law firms for about 10 years and a leading PRC law firm for about three years. Diane has extensive experiences in mergers and acquisitions, licencing transactions, private equity and venture capital investments. Diane holds a bachelor degree in law from Beijing University and a master degree in law from New York University School of Law.